Perspective Therapeutics (CATX) Change in Inventory (2010 - 2024)
Perspective Therapeutics' (CATX) quarterly Change in Inventory came in at $16000.0 in Q2 2024, up 200.0% year-over-year from $5333.3 in Q3 2023, and up 159.26% quarter-over-quarter from -$27000.0 in Q1 2024.
Powered by 
Analysis
Perspective Therapeutics (CATX) Change in Inventory (2010 - 2024) Analysis & Trends
Perspective Therapeutics has disclosed Change in Inventory across 15 years of filings, most recently posting $16000.0 for Q2 2024.
- In Q2 2024, Change in Inventory rose 200.0% year-over-year to $16000.0; the TTM figure through Jun 2025 stood at $16000.0 (up 107.08% YoY), while the FY2023 annual figure was -$359000.0, down 117.99% from the prior year.
- Change in Inventory came in at $16000.0 for Q2 2024 at Perspective Therapeutics, up from -$27000.0 in the prior quarter.
- In the past five years, Change in Inventory ranged from a high of $2.0 million in Q3 2022 to a low of -$1.3 million in Q4 2021.
- Average Change in Inventory over 5 years is $193055.6, with a median of $28000.0 recorded in 2020.
- Year-over-year, Change in Inventory slumped 5836.36% in 2021 and jumped 1343.61% in 2022.
- Over 5 years, Change in Inventory stood at $22000.0 in 2020, then plunged by 5836.36% to -$1.3 million in 2021, then soared by 106.02% to $76000.0 in 2022, then slumped by 234.21% to -$102000.0 in 2023, then surged by 115.69% to $16000.0 in 2024.
- Per Business Quant data, the three most recent Change in Inventory figures were $16000.0 in Q2 2024, -$27000.0 in Q1 2024, and -$102000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 31.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 145.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 27.70 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 28.20 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 132.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | -280,000.00 |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -75.70 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 12.97 Mn |
| 10 | Perspective Therapeutics | 358.23 Mn | 358.23 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 16,000.00 |
| Mar 31, 2024 | -27,000.00 |
| Dec 31, 2023 | -102,000.00 |
| Sep 30, 2023 | -113,000.00 |
| Jun 30, 2023 | -16,000.00 |
| Mar 31, 2023 | -128,000.00 |
| Dec 31, 2022 | 76,000.00 |
| Sep 30, 2022 | 2.02 Mn |
| Jun 30, 2022 | 1.92 Mn |
| Mar 31, 2022 | -84,000.00 |
| Dec 31, 2021 | -1.26 Mn |
| Sep 30, 2021 | 796,000.00 |
| Jun 30, 2021 | 133,000.00 |
| Mar 31, 2021 | 56,000.00 |
| Dec 31, 2020 | 22,000.00 |
| Sep 30, 2020 | 63,000.00 |
| Jun 30, 2020 | 76,000.00 |
| Mar 31, 2020 | 34,000.00 |
| Dec 31, 2019 | 26,000.00 |
| Sep 30, 2019 | -39,000.00 |